Cancer prevention drug also reduces virulence of H. pylori bacterium

Conference name: 2nd International conference on pathology

Short name: Pathology 2019

Venue : Paris,France | July 5-6,2019

URL: https://bit.ly/2GS09CI

The investigators found that in addition to its known ability to block the production of cell growth compounds, the drug DFMO (difluoromethylornithine) acts directly on the bacterium Helicobacter pylori to reduce its virulence. H. pylori infection is the primary cause of gastric cancer.

H. pylori infects the stomachs of half of the human population, but only about 1 percent of infected individuals develop stomach cancer. Although it's possible to treat the infection to prevent stomach cancer, it's not clear whom to treat. Plus, the bug may be conferring beneficial effects -- esophageal reflux diseases, asthma and other allergic disorders occur more frequently in people who are not infected with H. pylori.

To know more about Pathology and its Applications do attend International Conference on Pathology 2019 http://pathology.alliedacademies.com/

Contact
KRISTIE NOVA
Program Director | PATHOLOGY 2019
Phone: (44) 20 3769 1755
Email: pathology(at)alliedannualsummit(dot)com